Li Z, Gao J, Zheng S, Wang Y, Xiang X, Cheng Q
Turk J Gastroenterol. 2021; 32(1):30-41.
PMID: 33893764
PMC: 8975512.
DOI: 10.5152/tjg.2020.19877.
Wang Z, Wang E, Bai W, Xia D, Ding R, Li J
Liver Cancer. 2020; 9(3):308-325.
PMID: 32647633
PMC: 7325128.
DOI: 10.1159/000505692.
Yuan Y, Yu H, Mu S, Dong Y, Li D
Technol Cancer Res Treat. 2019; 18:1533033819851833.
PMID: 31570091
PMC: 6769208.
DOI: 10.1177/1533033819851833.
Wang F, Zhao W, Gao Y, Zhou J, Li H, Zhang G
J Exp Clin Cancer Res. 2019; 38(1):286.
PMID: 31272499
PMC: 6610961.
DOI: 10.1186/s13046-019-1297-6.
Lei X, Ke Y, Bao T, Tang H, Wu X, Shi Z
World J Clin Cases. 2018; 6(5):74-83.
PMID: 29774219
PMC: 5955731.
DOI: 10.12998/wjcc.v6.i5.74.
Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.
Zheng L, Guo C, Chen C, Xiao J, Hu H, Cheng H
Oncotarget. 2017; 8(57):97613-97622.
PMID: 29228637
PMC: 5722589.
DOI: 10.18632/oncotarget.18811.
Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma.
Catana C, Pichler M, Giannelli G, Mader R, Berindan-Neagoe I
Oncotarget. 2017; 8(17):29519-29534.
PMID: 28392501
PMC: 5438748.
DOI: 10.18632/oncotarget.15706.
Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L, Lin H, Li G, Sun Y, Shen J, Xu J
Cancer Lett. 2016; 373(1):45-56.
PMID: 26805759
PMC: 4887098.
DOI: 10.1016/j.canlet.2016.01.017.
Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.
Trovato F, Tognarelli J, Crossey M, Catalano D, Taylor-Robinson S, Trovato G
World J Hepatol. 2015; 7(26):2664-75.
PMID: 26609343
PMC: 4651910.
DOI: 10.4254/wjh.v7.i26.2664.
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N
Oncotarget. 2015; 7(3):2646-59.
PMID: 26544731
PMC: 4823061.
DOI: 10.18632/oncotarget.6104.
The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.
Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S
Biomed Res Int. 2015; 2015:731469.
PMID: 25893197
PMC: 4393929.
DOI: 10.1155/2015/731469.
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.
Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A
Biomed Res Int. 2014; 2014:203693.
PMID: 25089265
PMC: 4096380.
DOI: 10.1155/2014/203693.
Role of estrogen in hepatocellular carcinoma: is inflammation the key?.
Shi L, Feng Y, Lin H, Ma R, Cai X
J Transl Med. 2014; 12:93.
PMID: 24708807
PMC: 3992128.
DOI: 10.1186/1479-5876-12-93.
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R
BMC Cancer. 2014; 14:110.
PMID: 24552144
PMC: 3930857.
DOI: 10.1186/1471-2407-14-110.
